Trial Profile
The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2011
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LANTUSTITR
- Sponsors Sanofi
- 25 Aug 2011 Additional drug company added in associations field as reported by European Clinical Trials Database record.
- 28 Jan 2009 Actual patient numbers (4) added as reported by ClinicalTrials.gov.
- 28 Jan 2009 Actual initiation date changed from May 2006 to Sep 2006 as reported by ClinicalTrials.gov.